Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Operating Leases (2019 - 2025)

Historic Operating Leases for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $88.1 million.

  • Legend Biotech's Operating Leases rose 9300.62% to $88.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.1 million, marking a year-over-year increase of 9300.62%. This contributed to the annual value of $44.6 million for FY2024, which is 100.52% up from last year.
  • Latest data reveals that Legend Biotech reported Operating Leases of $88.1 million as of Q3 2025, which was up 9300.62% from $71.7 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Operating Leases registered a high of $88.1 million during Q3 2025, and its lowest value of $2.5 million during Q4 2021.
  • In the last 5 years, Legend Biotech's Operating Leases had a median value of $44.4 million in 2023 and averaged $45.5 million.
  • As far as peak fluctuations go, Legend Biotech's Operating Leases tumbled by 2576.34% in 2021, and later surged by 84257.19% in 2022.
  • Legend Biotech's Operating Leases (Quarter) stood at $2.5 million in 2021, then surged by 842.57% to $23.6 million in 2022, then skyrocketed by 87.14% to $44.2 million in 2023, then rose by 1.01% to $44.6 million in 2024, then skyrocketed by 97.39% to $88.1 million in 2025.
  • Its last three reported values are $88.1 million in Q3 2025, $71.7 million for Q2 2025, and $51.7 million during Q1 2025.